Profound Medical is a medical device company that develops AI-powered, MRI-guided ablation systems for minimally invasive tissue treatment. The company's lead product, TULSA-PRO, combines real-time MRI thermometry with robotic thermal ultrasound delivery to treat prostate cancer and benign prostatic hyperplasia through a transurethral approach, while its Sonalleve platform, acquired from Philips, delivers focused ultrasound for treating conditions including uterine fibroids, adenomyosis, and bone metastases. The company generates revenue through capital equipment sales and recurring revenue from single-use disposable devices and clinical services, with systems distributed to urologists, radiologists, and hospitals globally, and competes against traditional surgical, radiation, and alternative focal ablation therapies by offering millimeter-precision thermal control, rapid patient recovery, and outpatient feasibility.